Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10608)	7/2/1999 11:02:00 AM
From: opalapril	Read Replies (1) \| Respond to of 17367

George: Back to the future for a moment, please. I'm not sure I quite understand how the DSMB got pushed aside in the Neuprex P-3 trial, if in fact it was. Did the DSMB make any kind of written analysis? Interim report? Final report? Recommendation to the FDA? I ask because it seems passing strange the FDA would have allowed the trial to be halted w/o some scientific input on the trial's progress, and stranger still to empanel a DSMB, have them meet several times, and then shuffle their mortals coils off to Buffalo without so much as a fair-thee-well. In short, I believe there must be a recent data report in existence and Xoma or at least a select number of execs must know its contents, as before with every other interim DSMB analysis.